In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to EHRA Ivory (& above) Members, Fellows of the ESC and Young combined Members

Italian multicenter experience with a new active fixation quadripolar left ventricular lead

Session Rapid Fire 5: improving the response to cardiac resynchronization therapy: emerging technologies

Speaker Matteo Ziacchi

Congress : EHRA 2019

  • Topic : arrhythmias and device therapy
  • Sub-topic : Cardiac Resynchronization Therapy
  • Session type : Rapid Fire Abstracts
  • FP Number : 922

Authors : M Ziacchi (Bologna,IT), T Infusino (Catanzaro,IT), M Mezzetti (Urbino,IT), F Urraro (Benevento,IT), S Savastano (Pavia,IT), F Solimene (Mercogliano,IT), M Landolina (Crema,IT), A Capucci (Ancona,IT), S Iacopino (Cotignola,IT), G Luzzi (Bari,IT), R Foti (Taormina,IT), T Agricola (Pescara,IT), D Pecora (Brescia,IT), W Rauhe (Bolzano,IT), M Biffi (Bologna,IT)

15 views

Authors:
M Ziacchi1 , T Infusino2 , M Mezzetti3 , F Urraro4 , S Savastano5 , F Solimene6 , M Landolina7 , A Capucci8 , S Iacopino9 , G Luzzi10 , R Foti11 , T Agricola12 , D Pecora13 , W Rauhe14 , M Biffi1 , 1University Hospital Policlinic S. Orsola-Malpighi - Bologna - Italy , 2S.Anna Hospital - Catanzaro - Italy , 3Ospedale S. M. della Misericordia - Urbino - Italy , 4A. O. Rummo - Benevento - Italy , 5Policlinic Foundation San Matteo IRCCS - Pavia - Italy , 6Montevergine Cardiology Clinic - Mercogliano - Italy , 7Maggiore Hospital of Crema - Crema - Italy , 8AO Torrette-Umberto I-Lancisi - Ancona - Italy , 9Maria Cecilia Hospital - Cotignola - Italy , 10Polyclinic Hospital of Bari - Bari - Italy , 11S. Vincenzo Hospital - Taormina - Italy , 12S. Spirito Hospital - Pescara - Italy , 13Poliambulanza Foundation Hospital Institute of Brescia - Brescia - Italy , 14S. Maurizio Hospital - Bolzano - Italy ,

Citation:

Aim: To evaluate implant success rate and acute performance of a new quadripolar active fixation left ventricular lead (QAF). The exclusive fixation system consists of an exposed side helix for fixation to the vein wall. A narrow space between central electrodes ("Short dipole") was designed to reduce phrenic nerve stimulation risk.

Methods: 191 patients (72% male, 73±9 years, 60% NYHA III-IV, QRS width 152±26 ms) in 29 Italian hospitals received QAF between September 2017 and April 2018.

Results: QAF was successfully implanted in 185 (96.8%) and in 172 (94%) it was placed in the target area, as declared after coronary venogram. Median time for lead positioning was 15 minutes (25th-75th percentile: 5-30). No complications occurred during procedure. Pacing was basal in 37% patients, middle in 61% and apical in 2%. Short dipole was programmed in 16.8% patients. Mean implant pacing threshold (@0.4ms) was 1.3±1.1V, sensing 10.8±6.4mV and impedance 700.0±265.5W, comparable to other Medtronic LV leads. During 3.3 (1.3-4.8) months of follow-up 1 QAF dislodgement occurred 20 days after implantation and it was replaced by another QAF.

In 185 procedures (96.8%) the physicians judged the lead performance good/excellent and in 189 (98.9%) they ranked the easiness of fixation good/excellent.

Conclusion: The Attain Stability Quad lead allows stable placement in different cardiac veins, with high success rate and good handling performance. This lead is a valuable tool for LV pacing in desired target areas, even in case of high dislodgement risk or need of myocardial/phrenic threshold management.

The free consultation period for this content is over.

It is now only available year-round to EHRA Ivory (& above) Members, Fellows of the ESC and Young combined Members



Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, and Novartis Pharma AG. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are